trial representativeness

Over the past decade, oncology drug development has undergone a profound scientific transformation. Biomarker-driven therapies, adaptive designs, and tissue-agnostic indications have expanded what is clinically possible. Yet the operational engine of clinical trials, patient identification and enrollment, has not evolved...